{"pmid":32462968,"title":"Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?","text":["Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?","Prior research on nanotechnologies in diagnostics, prevention and treatment of coronavirus infections is reviewed. Gold nanoparticles and semiconductor quantum dots in colorimetric and immunochromatographic assays, silica nanoparticles in a polymerase chain reaction and spike protein nanospheres as antigen carriers and adjuvants in vaccine formulations present notable examples in diagnostics and prevention, while uses of nanoparticles in coronavirus infection treatments have been merely sporadic. The current absence of antiviral therapeutics that specifically target human coronaviruses, including SARS-CoV-2, might be largely due to the underuse of nanotechnologies. Elucidating the interface between nanoparticles and coronaviruses is timely, but presents the only route to the rational design of precisely targeted therapeutics for coronavirus infections. Such a fundamental approach is also a viable prophylaxis against future pandemics of this type.","Nanomedicine (Lond)","Uskokovic, Vuk","32462968"],"abstract":["Prior research on nanotechnologies in diagnostics, prevention and treatment of coronavirus infections is reviewed. Gold nanoparticles and semiconductor quantum dots in colorimetric and immunochromatographic assays, silica nanoparticles in a polymerase chain reaction and spike protein nanospheres as antigen carriers and adjuvants in vaccine formulations present notable examples in diagnostics and prevention, while uses of nanoparticles in coronavirus infection treatments have been merely sporadic. The current absence of antiviral therapeutics that specifically target human coronaviruses, including SARS-CoV-2, might be largely due to the underuse of nanotechnologies. Elucidating the interface between nanoparticles and coronaviruses is timely, but presents the only route to the rational design of precisely targeted therapeutics for coronavirus infections. Such a fundamental approach is also a viable prophylaxis against future pandemics of this type."],"journal":"Nanomedicine (Lond)","authors":["Uskokovic, Vuk"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462968","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.2217/nnm-2020-0163","keywords":["covid-19","infectious disease","interface","nanoparticle","nanotechnology","vaccine"],"locations":["nanoparticles","nanoparticles"],"e_drugs":["Silicon Dioxide"],"topics":["Treatment"],"weight":1,"_version_":1668079521449902080,"score":9.490897,"similar":[{"pmid":32486364,"title":"Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.","text":["Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.","Viral infections have recently emerged not only as a health threat to people but rapidly became the cause of universal fatality on a large scale. Nanomaterials comprising functionalized nanoparticles (NPs) and quantum dots and nanotechnology-associated innovative detection methods, vaccine design, and nanodrug production have shown immense promise for interfacing with pathogenic viruses and restricting their entrance into cells. These viruses have been scrutinized using rapid diagnostic detection and therapeutic interventional options against the caused infections including vaccine development for prevention and control. Coronaviruses, namely SARS-CoV, MERS-CoV, and SARS-CoV-2, have endangered human life, and the COVID-19 (caused by SARS-CoV-2) outbreak has become a perilous challenge to public health globally with huge accompanying morbidity rates. Thus, it is imperative to expedite the drug and vaccine development efforts that would help mitigate this pandemic. In this regard, smart and innovative nano-based technologies and approaches encompassing applications of green nanomedicine, bio-inspired methods, multifunctional bioengineered nanomaterials, and biomimetic drug delivery systems/carriers can help resolve the critical issues regarding detection, prevention, and treatment of viral infections. This perspective review expounds recent nanoscience advancements for the detection and treatment of viral infections with focus on coronaviruses and encompasses nano-based formulations and delivery platforms, nanovaccines, and promising methods for clinical diagnosis, especially regarding SARS-CoV-2.","Nanomaterials (Basel)","Nasrollahzadeh, Mahmoud","Sajjadi, Mohaddeseh","Soufi, Ghazaleh Jamalipour","Iravani, Siavash","Varma, Rajender S","32486364"],"abstract":["Viral infections have recently emerged not only as a health threat to people but rapidly became the cause of universal fatality on a large scale. Nanomaterials comprising functionalized nanoparticles (NPs) and quantum dots and nanotechnology-associated innovative detection methods, vaccine design, and nanodrug production have shown immense promise for interfacing with pathogenic viruses and restricting their entrance into cells. These viruses have been scrutinized using rapid diagnostic detection and therapeutic interventional options against the caused infections including vaccine development for prevention and control. Coronaviruses, namely SARS-CoV, MERS-CoV, and SARS-CoV-2, have endangered human life, and the COVID-19 (caused by SARS-CoV-2) outbreak has become a perilous challenge to public health globally with huge accompanying morbidity rates. Thus, it is imperative to expedite the drug and vaccine development efforts that would help mitigate this pandemic. In this regard, smart and innovative nano-based technologies and approaches encompassing applications of green nanomedicine, bio-inspired methods, multifunctional bioengineered nanomaterials, and biomimetic drug delivery systems/carriers can help resolve the critical issues regarding detection, prevention, and treatment of viral infections. This perspective review expounds recent nanoscience advancements for the detection and treatment of viral infections with focus on coronaviruses and encompasses nano-based formulations and delivery platforms, nanovaccines, and promising methods for clinical diagnosis, especially regarding SARS-CoV-2."],"journal":"Nanomaterials (Basel)","authors":["Nasrollahzadeh, Mahmoud","Sajjadi, Mohaddeseh","Soufi, Ghazaleh Jamalipour","Iravani, Siavash","Varma, Rajender S"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32486364","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/nano10061072","keywords":["covid-19","sars-cov-2","coronaviruses","graphene oxide","nanoparticles","nanotechnology","nanovaccines","quantum dots","viral infections"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668892169416474625,"score":405.2392},{"pmid":32378459,"title":"Application of nanomaterials in treatment, anti-infection and detection of coronaviruses.","text":["Application of nanomaterials in treatment, anti-infection and detection of coronaviruses.","Nanotechnology and nanomedicine have excellent potential in dealing with a range of different health problems, including viruses, which are considered to be a serious challenge in the medical field. Application of nanobiotechnology could represent a new avenue for the treatment or disinfection of viruses. There is increasing concern regarding the control of coronaviruses, among these, Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2 are well known and dangerous examples. This article aims to provide an overview of recent studies on the effectiveness of nanoparticles as diagnostic or antiviral tools against coronaviruses. The possibilities of effectively using nanomaterials as vaccines and nanosensors in this field are also presented.","Nanomedicine (Lond)","Nikaeen, Ghazal","Abbaszadeh, Sepideh","Yousefinejad, Saeed","32378459"],"abstract":["Nanotechnology and nanomedicine have excellent potential in dealing with a range of different health problems, including viruses, which are considered to be a serious challenge in the medical field. Application of nanobiotechnology could represent a new avenue for the treatment or disinfection of viruses. There is increasing concern regarding the control of coronaviruses, among these, Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2 are well known and dangerous examples. This article aims to provide an overview of recent studies on the effectiveness of nanoparticles as diagnostic or antiviral tools against coronaviruses. The possibilities of effectively using nanomaterials as vaccines and nanosensors in this field are also presented."],"journal":"Nanomedicine (Lond)","authors":["Nikaeen, Ghazal","Abbaszadeh, Sepideh","Yousefinejad, Saeed"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378459","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.2217/nnm-2020-0117","keywords":["covid-19","antiviral","bio-labeling","coronaviruses","gold nanoparticles","protein nanoparticles","severe acute respiratory syndrome coronavirus","silver nanoparticles","transmissible gastroenteritis virus","vaccine nanotechnology"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666262687663783937,"score":259.9865},{"pmid":32483428,"pmcid":"PMC7254986","title":"Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.","text":["Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.","On the 30(th) of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe. In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infection. In addition, they allow monitoring infectious sides and treatment responses using noninvasive imaging modalities. While intranasal delivery was proposed as the preferred administration route for therapeutic agents against viral pulmonary diseases, NP-based delivery systems offer numerous benefits to overcome challenges associated with mucosal administration, and ensure that these agents achieve a concentration that is many times higher than expected in the targeted sites of infection while limiting side effects on normal cells. In this article, we have shed light on the promising role of nanoparticles as effective carriers for therapeutics or immune modulators to help in fighting against COVID-19.","Theranostics","Itani, Rasha","Tobaiqy, Mansour","Al Faraj, Achraf","32483428"],"abstract":["On the 30(th) of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe. In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infection. In addition, they allow monitoring infectious sides and treatment responses using noninvasive imaging modalities. While intranasal delivery was proposed as the preferred administration route for therapeutic agents against viral pulmonary diseases, NP-based delivery systems offer numerous benefits to overcome challenges associated with mucosal administration, and ensure that these agents achieve a concentration that is many times higher than expected in the targeted sites of infection while limiting side effects on normal cells. In this article, we have shed light on the promising role of nanoparticles as effective carriers for therapeutics or immune modulators to help in fighting against COVID-19."],"journal":"Theranostics","authors":["Itani, Rasha","Tobaiqy, Mansour","Al Faraj, Achraf"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483428","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.7150/thno.46691","keywords":["covid-19","drug delivery systems","nanomedicine","theranostic nanoparticles"],"topics":["Treatment"],"weight":1,"_version_":1668532114727895040,"score":216.71965},{"pmid":32395098,"pmcid":"PMC7210793","title":"Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity.","text":["Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity.","Abstract: Vulnerability of respiratory mucosa to invasions of airborne pathogens, such as SARS-CoV, MERS-CoV and avian viruses which sometimes cause a life-threatening epidemic and even pandemic, underscores significance of developing a pulmonary vaccine adjuvant-delivery system (VADS). Herein, 30-nm aluminum nanoparticles (ANs), unlike the mostly used adjuvant alum which is unsuitable for delivering pulmonary vaccines due to side effects, proved able to act as a VADS fitting inhalation immunization to elicit wide-spread anti-antigen immunity. In vitro ANs facilitated cellular uptake of their cargos and, after pulmonary vaccination, induced mouse production of high levels of anti-antigen IgG in serum and IgA in saliva, nasal, bronchoalveolar and also vaginal fluids. Besides, IFN-gamma and anti-antigen IgG2a enriched in immunized mice which meanwhile showed no obvious lung inflammation indicated balanced Th1/Th2 responses were safely induced. These outcomes suggest ANs may be an efficient pulmonary VADS for defending against pathogens, especially, the ones invading hosts via respiratory system. Graphic Abstract: Aluminum nanoparticles can safely induce humoral and cellular immunity at systemic and mucosal level through pulmonary vaccination to contrast the conventional adjuvant alum.","J Inorg Organomet Polym Mater","Wang, Ning","Wei, Chunliu","Zhang, Zina","Liu, Ting","Wang, Ting","32395098"],"abstract":["Abstract: Vulnerability of respiratory mucosa to invasions of airborne pathogens, such as SARS-CoV, MERS-CoV and avian viruses which sometimes cause a life-threatening epidemic and even pandemic, underscores significance of developing a pulmonary vaccine adjuvant-delivery system (VADS). Herein, 30-nm aluminum nanoparticles (ANs), unlike the mostly used adjuvant alum which is unsuitable for delivering pulmonary vaccines due to side effects, proved able to act as a VADS fitting inhalation immunization to elicit wide-spread anti-antigen immunity. In vitro ANs facilitated cellular uptake of their cargos and, after pulmonary vaccination, induced mouse production of high levels of anti-antigen IgG in serum and IgA in saliva, nasal, bronchoalveolar and also vaginal fluids. Besides, IFN-gamma and anti-antigen IgG2a enriched in immunized mice which meanwhile showed no obvious lung inflammation indicated balanced Th1/Th2 responses were safely induced. These outcomes suggest ANs may be an efficient pulmonary VADS for defending against pathogens, especially, the ones invading hosts via respiratory system. Graphic Abstract: Aluminum nanoparticles can safely induce humoral and cellular immunity at systemic and mucosal level through pulmonary vaccination to contrast the conventional adjuvant alum."],"journal":"J Inorg Organomet Polym Mater","authors":["Wang, Ning","Wei, Chunliu","Zhang, Zina","Liu, Ting","Wang, Ting"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395098","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s10904-020-01572-z","keywords":["bioinorganic chemistry","cellular immunity","mucosal vaccination","nanocarrier","vaccine delivery"],"locations":["avian"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666627828082278400,"score":198.65416},{"pmid":32437124,"title":"Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles.","text":["Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles.","The current outbreak of the pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) demands its rapid, convenient, and large-scale diagnosis to downregulate its spread within as well as across the communities. But the reliability, reproducibility, and selectivity of majority of such diagnostic tests fail when they are tested either to a viral load at its early representation or to a viral gene mutated during its current spread. In this regard, a selective 'naked-eye' detection of SARS-CoV-2 is highly desirable, which can be tested without accessing any advanced instrumental techniques. We herein report the development of a colorimetric assay based on gold nanoparticles (AuNPs), those when capped with suitably designed thiol modified antisense oligonucleotides (ASOs) specific for N-gene (nucleocapsid phosphoprotein) of SARS-CoV-2, could be used for diagnosing positive COVID-19 cases within 10 minutes from the isolated RNA samples. The thiol modified ASO capped AuNPs agglomerate selectively in the presence of its target RNA sequence of SARS-CoV-2 and demonstrate a change in its surface plasmon resonance (SPR). Further, the addition of RNaseH cleaves the RNA strand from the RNA-DNA hybrid leading to a visually detectable precipitate from the solution mediated by the additional agglomeration among the AuNPs. The selectivity of the assay has been monitored in presence of MERS-CoV viral RNA with a limit of detection of 0.18 ng/microL of RNA having SARS-CoV-2 viral load. Thus, the current study reports a selective, and visual 'naked-eye' detection of COVID-19 causative virus, SARS-CoV-2, without the requirement of any sophisticated instrumental techniques.","ACS Nano","Moitra, Parikshit","Alafeef, Maha","Dighe, Ketan","Frieman, Matt","Pan, Dipanjan","32437124"],"abstract":["The current outbreak of the pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) demands its rapid, convenient, and large-scale diagnosis to downregulate its spread within as well as across the communities. But the reliability, reproducibility, and selectivity of majority of such diagnostic tests fail when they are tested either to a viral load at its early representation or to a viral gene mutated during its current spread. In this regard, a selective 'naked-eye' detection of SARS-CoV-2 is highly desirable, which can be tested without accessing any advanced instrumental techniques. We herein report the development of a colorimetric assay based on gold nanoparticles (AuNPs), those when capped with suitably designed thiol modified antisense oligonucleotides (ASOs) specific for N-gene (nucleocapsid phosphoprotein) of SARS-CoV-2, could be used for diagnosing positive COVID-19 cases within 10 minutes from the isolated RNA samples. The thiol modified ASO capped AuNPs agglomerate selectively in the presence of its target RNA sequence of SARS-CoV-2 and demonstrate a change in its surface plasmon resonance (SPR). Further, the addition of RNaseH cleaves the RNA strand from the RNA-DNA hybrid leading to a visually detectable precipitate from the solution mediated by the additional agglomeration among the AuNPs. The selectivity of the assay has been monitored in presence of MERS-CoV viral RNA with a limit of detection of 0.18 ng/microL of RNA having SARS-CoV-2 viral load. Thus, the current study reports a selective, and visual 'naked-eye' detection of COVID-19 causative virus, SARS-CoV-2, without the requirement of any sophisticated instrumental techniques."],"journal":"ACS Nano","authors":["Moitra, Parikshit","Alafeef, Maha","Dighe, Ketan","Frieman, Matt","Pan, Dipanjan"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437124","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1021/acsnano.0c03822","e_drugs":["Oligonucleotides","Oligonucleotides, Antisense","Sulfhydryl Compounds"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393804181504,"score":176.26874}]}